Table 1.
Patient baseline characteristics grouped by DAS28-hsCRP and treatment
| DAS28-Group A (N = 212) | DAS28-Group B (N = 372) | |||||
|---|---|---|---|---|---|---|
| Treatment (N; % of treatment group) | MTX (N = 45; 21.4%) | Bari (N = 67; 42.1%) | Bari + MTX(N = 100; 46.5%) | MTX (N = 165; 78.6%) | Bari (N = 92; 57.9%) | Bari + MTX (N = 115; 53.5%) |
| Age, (years) | 52 ± 14 | 52 ± 13 | 46 ± 14 | 50 ± 13 | 50 ± 13 | 51 ± 13 |
| Female | 31 (68.9) | 49 (73.1) | 71 (71.0) | 117 (70.9) | 72 (78.3) | 85 (73.9) |
| BMI, (kg/m2) | 25.1 ± 5.1 | 27.5 ± 7.3 | 25.2 ± 5.1 | 26.9 ± 6.4 | 26.4 ± 6.1 | 27.8 ± 6.4 |
| Smoker | 7 (15.6) | 16 (23.9) | 21 (21.0) | 41 (24.8) | 21 (22.8) | 26 (22.6) |
| Duration of RA from diagnosis, (years)a | 0.2 (0.1, 0.3) | 0.2 (0.1, 0.5) | 0.2 (0.1, 1.0) | 0.2 (0.1, 0.7) | 0.4 (0.1, 1.4) | 0.3 (0.1, 1.0) |
| ACPA positiveb | 41 (91.1) | 63 (94.0) | 94 (94.0) | 152 (92.7) | 79 (85.9) | 98 (85.2) |
| RF positivec | 43 (95.6) | 67 (100.0) | 94 (94.0) | 160 (97.0) | 88 (95.7) | 110 (95.7) |
| ≥ 1 joint erosion | 28 (62.2) | 43 (64.2) | 60 (60.0) | 110 (67.1) | 62 (67.4) | 77 (67.0) |
| hsCRP (mg/L) | 14.5 ± 10.8 | 20.5 ± 19.7 | 25.2 ± 27.5 | 24.5 ± 23.5 | 26.1 ± 30.0 | 23.5 ± 31.1 |
| DAS28-hsCRP | 5.5 ± 0.9 | 5.7 ± 0.9 | 5.8 ± 1.0 | 5.9 ± 1.0 | 6.1 ± 1.0 | 6.0 ± 0.9 |
| SDAI | 37.7 ± 12.6 | 38.6 ± 12.0 | 40.0 ± 13.2 | 42.7 ± 14.1 | 45.6 ± 14.6 | 45.2 ± 13.0 |
| mTSS | 10.2 ± 23.5 | 11.8 ± 28.5 | 9.7 ± 17.5 | 12.3 ± 21.8 | 14.4 ± 26.0 | 13.1 ± 22.3 |
| HAQ-DI total score | 1.5 ± 0.7 | 1.6 ± 0.7 | 1.5 ± 0.7 | 1.7 ± 0.7 | 1.7 ± 0.7 | 1.6 ± 0.6 |
Data are reported as mean ± standard deviation or n (%) unless otherwise indicated. DAS28-group A: sustained DAS28-hsCRP ≤ 3.2 at weeks 16, 20, and 24; DAS28-group B: DAS28-hsCRP > 3.2 or missing data at any of weeks 16, 20, and 24
aData presented as medians with interquartile range
bACPA positive (> ULN [ULN = 10 U/mL])
cRF positive (> ULN [ULN = 14 U/mL])
ACPA anti-cyclic citrullinated peptide antibody, Bari baricitinib, DAS28 Disease Activity Score for 28-joint counts, BMI body mass index, HAQ-DI Health Assessment Questionnaire-Disability Index, hsCRP high-sensitivity C-reactive protein, mTSS van der Heijde-modified total Sharp score, MTX methotrexate, RA rheumatoid arthritis, RF rheumatoid factor, SDAI Simplified Disease Activity Index, ULN upper limit of normal